Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer-Killing virus combined with keytruda shows promise in stubborn tumors

NCT ID NCT06340711

Recruiting now Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into their tumor during a scope procedure, plus infusions of the immunotherapy drug pembrolizumab (Keytruda). The goal is to see if this combination is safe and effective in shrinking tumors or controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OBP-301 (a virus injected into the tumor) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to
If it works, this combination could offer a new treatment option for people with hard-to-treat stomach or esophageal cancers that don't respond to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The virus injection requires a scope procedure, and side effects from both drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.